BRISBANE, Calif., Oct. 17 /PRNewswire-FirstCall/ -- CoTherix, Inc. announced today that it will release results for the third quarter of 2006 after close of the stock market on Wednesday, November 1, 2006.
Company management will also host a conference call at 2:00 p.m. PST on November 1 to discuss third quarter 2006 results. The dial-in number for domestic callers will be (800) 309-2906 and for international callers will be (706) 634-0903. The conference ID number is 7556212.
To listen to the live webcast of the conference call please go to www.cotherix.com and click on the “Investor Relations” link. There will be a replay available for approximately two weeks following the call. The conference call, replay and webcast are open to all interested parties.
About CoTherix, Inc.
CoTherix, Inc. is a biopharmaceutical company focused on licensing, developing and commercializing therapeutic products for the treatment of cardiovascular disease, including pulmonary arterial hypertension (PAH) and stable angina. CoTherix currently markets Ventavis(R) (iloprost) Inhalation Solution in the United States for the treatment of PAH (WHO Group I). CoTherix and the CoTherix logo are trademarks of CoTherix, Inc. Ventavis is a registered trademark of Schering AG, Germany. More information can be found at www.cotherix.com and www.4Ventavis.com.
CoTherix, Inc.
CONTACT: Anne Bowdidge, Senior Director of Investor Relations of CoTherix,Inc., +1-650-808-6551
Web site: http://www.cotherix.com//
